MA45404A - Anticorps monoclonaux humanisés et chimériques dirigés contre cd81 - Google Patents

Anticorps monoclonaux humanisés et chimériques dirigés contre cd81

Info

Publication number
MA45404A
MA45404A MA045404A MA45404A MA45404A MA 45404 A MA45404 A MA 45404A MA 045404 A MA045404 A MA 045404A MA 45404 A MA45404 A MA 45404A MA 45404 A MA45404 A MA 45404A
Authority
MA
Morocco
Prior art keywords
chemerical
humanized
monoclonal antibodies
directed against
antibodies directed
Prior art date
Application number
MA045404A
Other languages
English (en)
Inventor
Chiung-Chi Kuo
Ronald Levy
Shoshana Levy
Jie Liu
Aurelien Marabelle
Ranjani Rajapaksa
Felipe Vences-Catalán
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MA45404A publication Critical patent/MA45404A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA045404A 2016-06-16 2017-06-14 Anticorps monoclonaux humanisés et chimériques dirigés contre cd81 MA45404A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16

Publications (1)

Publication Number Publication Date
MA45404A true MA45404A (fr) 2019-04-24

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045404A MA45404A (fr) 2016-06-16 2017-06-14 Anticorps monoclonaux humanisés et chimériques dirigés contre cd81

Country Status (9)

Country Link
US (1) US10815306B2 (fr)
EP (1) EP3471762A4 (fr)
JP (1) JP2019517813A (fr)
CN (1) CN109414492A (fr)
BR (1) BR112018076247A2 (fr)
CA (1) CA3027942A1 (fr)
MA (1) MA45404A (fr)
RU (1) RU2019100102A (fr)
WO (1) WO2017218691A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230068783A1 (en) * 2020-01-21 2023-03-02 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with il-1beta receptor signalling
WO2024079192A1 (fr) 2022-10-12 2024-04-18 Institut National de la Santé et de la Recherche Médicale Cd81 utilisé en tant que biomarqueur et cible biologique dans des malignités de lymphocytes t

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (fr) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
AU2005291486A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
WO2006117782A2 (fr) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Anticorps recombinants diriges contre cd55 et cd59 et leur utilisation
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP1790664A1 (fr) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
JP5769316B2 (ja) 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
WO2011156520A2 (fr) 2010-06-09 2011-12-15 Green Pacific Biologicals, Inc. Compositions et procédés pour l'accroissement de la production et de la sécrétion d'huile
KR20130132904A (ko) * 2010-12-06 2013-12-05 다이닛본 스미토모 세이야꾸 가부시끼가이샤 인간 모노클로날 항체
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
WO2014063368A1 (fr) * 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 Anticorps monoclonal humanisé dans un domaine extracellulaire de l'anti-récepteur de mort humain 5

Also Published As

Publication number Publication date
WO2017218691A1 (fr) 2017-12-21
BR112018076247A2 (pt) 2019-03-26
CN109414492A (zh) 2019-03-01
US10815306B2 (en) 2020-10-27
JP2019517813A (ja) 2019-06-27
EP3471762A1 (fr) 2019-04-24
RU2019100102A (ru) 2020-07-16
US20190177425A1 (en) 2019-06-13
CA3027942A1 (fr) 2017-12-21
RU2019100102A3 (fr) 2020-10-14
EP3471762A4 (fr) 2020-03-11

Similar Documents

Publication Publication Date Title
ZA201902533B (en) Anti-pd-l1 antibodies and variants
DK3455257T3 (da) Anti-pd-l1-antistoffer
HK1259426A1 (zh) Pd-l1抗體及其用途
HK1255604A1 (zh) 抗pd-l1抗體及其用途
IL262092B (en) Anti-pacap antibodies from humans and their use
DK3389699T3 (da) Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
SG11201705252UA (en) Anti-pd-1 monoclonal antibodies and obtaining method thereof
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3191135T3 (da) Anti-HER2-antistoffer og immunokonjugater
DK3441086T3 (da) Monoklonalt anti-PD-1-antistof
EP3459973A4 (fr) Anticorps monoclonal humanisé anti-pd-l1 humaine et son utilisation
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
DK3286223T3 (da) Kappa myeloma antigen chimær antigen receptorer og anvendelser deraf
IL286208A (en) Monoclonal antibodies of human origin and methods of using them
KR20180085002A (ko) 인간화된 항-cll-1 항체
ZA202006797B (en) Anti-rsv monoclonal antibody formulation
DK3280440T3 (da) Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
IL258924A (en) Humanized anti-Dicoff-related protein 2 antibody and uses thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
MA50222A (fr) Anticorps bispécifiques anti-pd-l1-anti-tim-3
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3209686T3 (da) Monoklonale anti-gpc-1-antistoffer og anvendelser deraf